Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics ($ELVN), sold shares on the open market 14 times over the past year, totaling nearly $859,100. His most recent sale occurred on March 6, 2026. These transactions rank him 5,281st among 11,678 insiders by sale value, below the average of $8.6 million per insider and 6.4 transactions. Hohl made no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 6, 2026 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 10000 | $29.58 | 51,000.0000 | 62,093,795 | 16.39% | 0.02% |
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | A | Common Stock | 25000 | $0.00 | 61,000.0000 | 62,093,795 | 69.44% | 0.04% |
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 62,093,795 | 9999.99% | 0.24% |
| Dec. 22, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 13000 | $2.48 | 36,000.0000 | 62,093,795 | 56.52% | 0.02% |
| Dec. 22, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 13000 | $0.00 | 92,056.0000 | 62,093,795 | 12.37% | 0.02% |
| Sept. 29, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 26,250.0000 | 47,072,532 | 14.13% | 0.01% |
| Sept. 29, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 105,056.0000 | 47,072,532 | 3.00% | 0.01% |
| Sept. 29, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $20.40 | 23,000.0000 | 47,072,532 | 12.38% | 0.01% |
| Aug. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 26,250.0000 | 47,072,532 | 14.13% | 0.01% |
| Aug. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 108,306.0000 | 47,072,532 | 2.91% | 0.01% |
| Aug. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $20.63 | 23,000.0000 | 47,072,532 | 12.38% | 0.01% |
| July 28, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3185 | $20.45 | 23,065.0000 | 47,072,532 | 12.13% | 0.01% |
| July 28, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 65 | $21.30 | 23,000.0000 | 47,072,532 | 0.28% | 0.00% |
| July 28, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 111,556.0000 | 47,072,532 | 2.83% | 0.01% |
| July 28, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 26,250.0000 | 47,072,532 | 14.13% | 0.01% |
| July 10, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 1000 | $2.48 | 24,000.0000 | 47,072,532 | 4.35% | 0.00% |
| July 10, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1000 | $22.66 | 23,000.0000 | 47,072,532 | 4.17% | 0.00% |
| July 10, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 1000 | $0.00 | 114,806.0000 | 47,072,532 | 0.86% | 0.00% |
| June 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 26,250.0000 | 47,072,532 | 14.13% | 0.01% |
| June 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 198 | $21.66 | 23,000.0000 | 47,072,532 | 0.85% | 0.00% |
| June 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 115,806.0000 | 47,072,532 | 2.73% | 0.01% |
| June 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3052 | $20.86 | 23,198.0000 | 47,072,532 | 11.63% | 0.01% |
| June 13, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3000 | $0.00 | 119,056.0000 | 47,072,532 | 2.46% | 0.01% |
| June 13, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3000 | $22.55 | 23,000.0000 | 47,072,532 | 11.54% | 0.01% |
| June 13, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3000 | $2.48 | 26,000.0000 | 47,072,532 | 13.04% | 0.01% |
| May 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $16.18 | 23,000.0000 | 47,072,532 | 12.38% | 0.01% |
| May 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 26,250.0000 | 47,072,532 | 14.13% | 0.01% |
| May 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 122,056.0000 | 47,072,532 | 2.59% | 0.01% |
| April 28, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3181 | $18.68 | 23,069.0000 | 47,072,532 | 12.12% | 0.01% |
| April 28, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 26,250.0000 | 47,072,532 | 14.13% | 0.01% |
| April 28, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 69 | $19.12 | 23,000.0000 | 47,072,532 | 0.30% | 0.00% |
| April 28, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 125,306.0000 | 47,072,532 | 2.53% | 0.01% |
| March 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 26,250.0000 | 47,072,532 | 14.13% | 0.01% |
| March 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 128,556.0000 | 47,072,532 | 2.47% | 0.01% |
| March 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $21.33 | 23,000.0000 | 47,072,532 | 12.38% | 0.01% |
| March 24, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 1000 | $0.00 | 131,806.0000 | 47,072,532 | 0.75% | 0.00% |
| March 24, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 1000 | $2.48 | 24,000.0000 | 47,072,532 | 4.35% | 0.00% |
| March 24, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1000 | $22.50 | 23,000.0000 | 47,072,532 | 4.17% | 0.00% |
| March 4, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 10000 | $2.48 | 23,000.0000 | 47,072,532 | 76.92% | 0.02% |
| March 4, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 10000 | $0.00 | 132,806.0000 | 47,072,532 | 7.00% | 0.02% |
| Feb. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 16,250.0000 | 47,072,532 | 25.00% | 0.01% |
| Feb. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 142,806.0000 | 47,072,532 | 2.23% | 0.01% |
| Feb. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $20.41 | 13,000.0000 | 47,072,532 | 20.00% | 0.01% |
| Feb. 6, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | A | Stock Option (right to buy) | 171000 | $0.00 | 171,000.0000 | 47,072,532 | 9999.99% | 0.36% |
| Feb. 5, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 1000 | $0.00 | 146,056.0000 | 47,072,532 | 0.68% | 0.00% |
| Feb. 5, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1000 | $22.52 | 13,000.0000 | 47,072,532 | 7.14% | 0.00% |
| Feb. 5, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 1000 | $2.48 | 14,000.0000 | 47,072,532 | 7.69% | 0.00% |
| Jan. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $21.59 | 13,000.0000 | 47,072,532 | 20.00% | 0.01% |
| Jan. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 147,056.0000 | 47,072,532 | 2.16% | 0.01% |
| Jan. 27, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 16,250.0000 | 47,072,532 | 25.00% | 0.01% |
| Jan. 3, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 1000 | $0.00 | 150,306.0000 | 47,072,532 | 0.66% | 0.00% |
| Dec. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 13000 | $0.00 | 155,556.0000 | 48,267,458 | 7.71% | 0.03% |
| Jan. 3, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1000 | $25.04 | 13,000.0000 | 47,072,532 | 7.14% | 0.00% |
| Jan. 3, 2025 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 1000 | $2.48 | 14,000.0000 | 47,072,532 | 7.69% | 0.00% |
| Dec. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 13000 | $2.48 | 13,000.0000 | 48,267,458 | 9999.99% | 0.03% |
| Dec. 30, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 900 | $2.48 | 900.0000 | 48,267,458 | 9999.99% | 0.00% |
| Dec. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3350 | $2.48 | 3,350.0000 | 48,267,458 | 9999.99% | 0.01% |
| Dec. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3350 | $22.15 | 0.0000 | 48,267,458 | 100.00% | 0.01% |
| Dec. 30, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 900 | $22.51 | 0.0000 | 48,267,458 | 100.00% | 0.00% |
| Dec. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3350 | $0.00 | 165,206.0000 | 48,267,458 | 1.99% | 0.01% |
| Dec. 30, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 900 | $0.00 | 164,306.0000 | 48,267,458 | 0.54% | 0.00% |
| Nov. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 4250 | $24.78 | 1,000.0000 | 48,267,458 | 80.95% | 0.01% |
| Nov. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1000 | $25.38 | 0.0000 | 48,267,458 | 100.00% | 0.00% |
| Nov. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 5250 | $0.00 | 168,556.0000 | 48,267,458 | 3.02% | 0.01% |
| Nov. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 5250 | $2.48 | 5,250.0000 | 48,267,458 | 9999.99% | 0.01% |
| Oct. 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 5600 | $28.49 | 650.0000 | 48,267,458 | 89.60% | 0.01% |
| Oct. 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 6250 | $0.00 | 173,806.0000 | 48,267,458 | 3.47% | 0.01% |
| Oct. 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 650 | $29.11 | 0.0000 | 48,267,458 | 100.00% | 0.00% |
| Oct. 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 6250 | $2.48 | 6,250.0000 | 48,267,458 | 9999.99% | 0.01% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 814 | $0.00 | 180,056.0000 | 48,267,458 | 0.45% | 0.00% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 814 | $2.48 | 814.0000 | 48,267,458 | 9999.99% | 0.00% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 814 | $30.00 | 0.0000 | 48,267,458 | 100.00% | 0.00% |
| Oct. 4, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 10218 | $2.48 | 10,218.0000 | 48,267,458 | 9999.99% | 0.02% |
| Oct. 7, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 1270 | $0.00 | 180,870.0000 | 48,267,458 | 0.70% | 0.00% |
| Oct. 4, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 10218 | $0.00 | 182,140.0000 | 48,267,458 | 5.31% | 0.02% |
| Oct. 7, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1270 | $27.51 | 0.0000 | 48,267,458 | 100.00% | 0.00% |
| Oct. 4, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 10218 | $27.51 | 0.0000 | 48,267,458 | 100.00% | 0.02% |
| Oct. 7, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 1270 | $2.48 | 2,000.0000 | 48,267,458 | 173.97% | 0.00% |
| Oct. 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 521 | $2.48 | 521.0000 | 48,267,458 | 9999.99% | 0.00% |
| Oct. 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 521 | $27.54 | 0.0000 | 48,267,458 | 100.00% | 0.00% |
| Oct. 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 521 | $0.00 | 192,358.0000 | 48,267,458 | 0.27% | 0.00% |
| Sept. 30, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 2000 | $0.00 | 192,879.0000 | 35,546,215 | 1.03% | 0.01% |
| Sept. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 4250 | $2.48 | 4,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| Sept. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 4250 | $24.27 | 0.0000 | 35,546,215 | 100.00% | 0.01% |
| Sept. 30, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 2000 | $2.48 | 2,000.0000 | 35,546,215 | 9999.99% | 0.01% |
| Sept. 30, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 2000 | $25.33 | 0.0000 | 35,546,215 | 100.00% | 0.01% |
| Sept. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 4250 | $0.00 | 194,879.0000 | 35,546,215 | 2.13% | 0.01% |
| Aug. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 4250 | $22.54 | 0.0000 | 35,546,215 | 100.00% | 0.01% |
| Aug. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 4250 | $2.48 | 4,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| Aug. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 4250 | $0.00 | 199,129.0000 | 35,546,215 | 2.09% | 0.01% |
| July 31, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 991 | $0.00 | 203,379.0000 | 35,546,215 | 0.48% | 0.00% |
| July 31, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 991 | $27.53 | 0.0000 | 35,546,215 | 100.00% | 0.00% |
| July 31, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 991 | $2.48 | 991.0000 | 35,546,215 | 9999.99% | 0.00% |
| July 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 61 | $27.44 | 0.0000 | 35,546,215 | 100.00% | 0.00% |
| July 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 5250 | $0.00 | 204,370.0000 | 35,546,215 | 2.50% | 0.01% |
| July 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 5250 | $2.48 | 5,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| July 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 5189 | $26.67 | 61.0000 | 35,546,215 | 98.84% | 0.01% |
| July 12, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3000 | $2.48 | 3,000.0000 | 35,546,215 | 9999.99% | 0.01% |
| July 12, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3000 | $25.07 | 0.0000 | 35,546,215 | 100.00% | 0.01% |
| July 12, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3000 | $0.00 | 209,620.0000 | 35,546,215 | 1.41% | 0.01% |
| June 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1140 | $23.43 | 0.0000 | 35,546,215 | 100.00% | 0.00% |
| June 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1280 | $21.79 | 2,970.0000 | 35,546,215 | 30.12% | 0.00% |
| June 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 4250 | $2.48 | 4,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| June 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1830 | $22.58 | 1,140.0000 | 35,546,215 | 61.62% | 0.01% |
| June 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 4250 | $0.00 | 212,620.0000 | 35,546,215 | 1.96% | 0.01% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 4250 | $2.48 | 4,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 4250 | $0.00 | 216,870.0000 | 35,546,215 | 1.92% | 0.01% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 10 | $24.34 | 0.0000 | 35,546,215 | 100.00% | 0.00% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 2334 | $23.42 | 10.0000 | 35,546,215 | 99.57% | 0.01% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1906 | $22.89 | 2,344.0000 | 35,546,215 | 44.85% | 0.01% |
| May 3, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 1000 | $22.50 | 0.0000 | 35,546,215 | 100.00% | 0.00% |
| May 3, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 1000 | $2.48 | 1,000.0000 | 35,546,215 | 9999.99% | 0.00% |
| May 3, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 1000 | $0.00 | 221,120.0000 | 35,546,215 | 0.45% | 0.00% |
| April 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 222,120.0000 | 35,546,215 | 1.44% | 0.01% |
| April 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 3,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| April 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $16.97 | 0.0000 | 35,546,215 | 100.00% | 0.01% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 14000 | $0.00 | 225,370.0000 | 35,546,215 | 5.85% | 0.04% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 14000 | $2.48 | 14,000.0000 | 35,546,215 | 9999.99% | 0.04% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3777 | $23.88 | 10,223.0000 | 35,546,215 | 26.98% | 0.01% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 10223 | $25.04 | 0.0000 | 35,546,215 | 100.00% | 0.03% |
| March 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 239,370.0000 | 35,546,215 | 1.34% | 0.01% |
| March 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 182 | $18.72 | 0.0000 | 35,546,215 | 100.00% | 0.00% |
| March 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3068 | $18.22 | 182.0000 | 35,546,215 | 94.40% | 0.01% |
| March 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 3,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| Feb. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 242,620.0000 | 35,546,215 | 1.32% | 0.01% |
| Feb. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $16.97 | 0.0000 | 35,546,215 | 100.00% | 0.01% |
| Feb. 27, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 3,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| Feb. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | A | Stock Option (right to buy) | 185000 | $0.00 | 185,000.0000 | 35,546,215 | 9999.99% | 0.52% |
| Jan. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S | Common Stock | 3250 | $15.81 | 0.0000 | 35,546,215 | 100.00% | 0.01% |
| Jan. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Stock Option (right to buy) | 3250 | $0.00 | 245,870.0000 | 35,546,215 | 1.30% | 0.01% |
| Jan. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M | Common Stock | 3250 | $2.48 | 3,250.0000 | 35,546,215 | 9999.99% | 0.01% |
| Jan. 2, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Common Stock | 9383 | $2.48 | 9,383.0000 | 35,546,215 | 9999.99% | 0.03% |
| Jan. 2, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | S | Common Stock | 9383 | $15.01 | 0.0000 | 35,546,215 | 100.00% | 0.03% |
| Dec. 28, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Employee Stock Option (right to buy) | 2467 | $0.00 | 258,523.0000 | 0 | 0.95% | 0.00% |
| Dec. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Employee Stock Option (right to buy) | 20 | $0.00 | 258,503.0000 | 0 | 0.01% | 0.00% |
| Jan. 2, 2024 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Employee Stock Option (right to buy) | 9383 | $0.00 | 249,120.0000 | 35,546,215 | 3.63% | 0.03% |
| Dec. 28, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Common Stock | 2467 | $2.48 | 2,467.0000 | 0 | 9999.99% | 0.00% |
| Dec. 28, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | S | Common Stock | 2467 | $15.07 | 0.0000 | 0 | 100.00% | 0.00% |
| Dec. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Common Stock | 20 | $2.48 | 20.0000 | 0 | 9999.99% | 0.00% |
| Dec. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | S | Common Stock | 20 | $15.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Employee Stock Option (right to buy) | 1030 | $0.00 | 261,090.0000 | 0 | 0.39% | 0.00% |
| Dec. 26, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | S | Common Stock | 100 | $15.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Dec. 26, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Employee Stock Option (right to buy) | 100 | $0.00 | 260,990.0000 | 0 | 0.04% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Common Stock | 1030 | $2.48 | 1,030.0000 | 0 | 9999.99% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | S | Common Stock | 1030 | $15.07 | 0.0000 | 0 | 100.00% | 0.00% |
| Dec. 26, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | M | Common Stock | 100 | $2.48 | 100.0000 | 0 | 9999.99% | 0.00% |
| April 4, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | A | Stock Option (right to buy) | 206000 | $0.00 | 206,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Hohl Benjamin | Chief Financial Officer | A | Employee Stock Option (right to buy) | 262120 | $0.00 | 262,120.0000 | 0 | 9999.99% | 0.00% |